GlaxoSmithKline plc (LON:GSK)’s share price reached a new 52-week low on Wednesday . The stock traded as low as GBX 1,270 ($17.09) and last traded at GBX 1,278 ($17.20), with a volume of 7551539 shares. The stock had previously closed at GBX 1,278 ($17.20).

Several equities analysts have weighed in on the company. Bryan, Garnier & Co reissued a “neutral” rating and set a GBX 1,710 ($23.01) price target on shares of GlaxoSmithKline in a research report on Tuesday, September 19th. Investec downgraded GlaxoSmithKline to a “hold” rating and dropped their price target for the stock from GBX 1,800 ($24.23) to GBX 1,390 ($18.71) in a research report on Monday, November 6th. Bank of America set a GBX 1,450 ($19.52) price target on GlaxoSmithKline and gave the stock a “neutral” rating in a research report on Wednesday. Shore Capital reissued a “hold” rating on shares of GlaxoSmithKline in a research report on Monday, October 23rd. Finally, Jefferies Group dropped their price target on GlaxoSmithKline from GBX 1,700 ($22.88) to GBX 1,540 ($20.73) and set a “buy” rating for the company in a research report on Tuesday, October 31st. Three equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and eight have assigned a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus price target of GBX 1,577.14 ($21.23).

GlaxoSmithKline (LON:GSK) last issued its quarterly earnings data on Wednesday, October 25th. The company reported GBX 32.50 ($0.44) EPS for the quarter, topping the Zacks’ consensus estimate of GBX 31.80 ($0.43) by GBX 0.70 ($0.01). The company had revenue of GBX 784.30 billion for the quarter. GlaxoSmithKline had a return on equity of 461.88% and a net margin of 17.79%.

The business also recently disclosed a dividend, which will be paid on Thursday, January 11th. Shareholders of record on Thursday, November 9th will be paid a dividend of GBX 19 ($0.26) per share. This represents a dividend yield of 1.41%. The ex-dividend date is Thursday, November 9th.

In other GlaxoSmithKline news, insider Urs Rohner bought 473 shares of the company’s stock in a transaction dated Wednesday, October 25th. The shares were acquired at an average cost of GBX 1,518 ($20.43) per share, with a total value of £7,180.14 ($9,663.71). Also, insider Simon Dingemans bought 1,076 shares of the company’s stock in a transaction dated Thursday, October 12th. The shares were acquired at an average cost of GBX 1,527 ($20.55) per share, for a total transaction of £16,430.52 ($22,113.76). In the last 90 days, insiders have acquired 1,576 shares of company stock worth $2,400,376.

COPYRIGHT VIOLATION WARNING: This news story was originally reported by TheOlympiaReport and is owned by of TheOlympiaReport. If you are viewing this news story on another site, it was illegally copied and republished in violation of international trademark and copyright laws. The correct version of this news story can be read at

About GlaxoSmithKline

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Receive News & Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related companies with Analyst Ratings Network's FREE daily email newsletter.